Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YL-15293 |
Synonyms | |
Therapy Description |
YL-15293 selectively inhibits KRAS G12C and leads to decreased downstream signaling, potentially resulting in anti-tumor activity (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YL-15293 | YL15293|YL 15293 | KRAS G12C inhibitor 34 | YL-15293 selectively inhibits KRAS G12C and leads to decreased downstream signaling, potentially resulting in anti-tumor activity (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05119933 | Phase Ib/II | YL-15293 | A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation | Unknown status | USA | 0 |